{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:13:10Z","timestamp":1791133990919,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"DOI":"10.1093\/jac\/dkr269","type":"journal-article","created":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T20:14:19Z","timestamp":1309292059000},"page":"2099-2106","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial"],"prefix":"10.1093","volume":"66","author":[{"given":"S\u00e9bastien","family":"Gallien","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Assistance Publique H\u00f4pitaux de Paris, Saint-Louis Hospital, Paris, France"},{"name":"University of Paris-Diderot Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9phine","family":"Braun","sequence":"additional","affiliation":[{"name":"INSERM SC10, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"University of Paris-Diderot Paris 7, Paris, France"},{"name":"Laboratory of Virology, Saint-Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Charreau","sequence":"additional","affiliation":[{"name":"INSERM SC10, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Gui de Chauliac University Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jeanblanc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, E. Herriot Hospital, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Verdon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, C\u00f4te de Nacre Hospital, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"de Truchis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Raymond Poincar\u00e9 Hospital, Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"May","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Brabois Hospital, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine-Chambrin","sequence":"additional","affiliation":[{"name":"Pharmacy, Saint-Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Aboulker","sequence":"additional","affiliation":[{"name":"INSERM SC10, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Assistance Publique H\u00f4pitaux de Paris, Saint-Louis Hospital, Paris, France"},{"name":"University of Paris-Diderot Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EASIER ANRS 138 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Balkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Calvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Korzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sereni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"key\n\t\t\t\t20180328160915_DKR269C1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328160915_DKR269C2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328160915_DKR269C3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328160915_DKR269C4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328160915_DKR269C5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir\u2013ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328160915_DKR269C6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/605674","article-title":"Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial","volume":"49","author":"De Castro","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328160915_DKR269C7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/QAD.0b013e328302f3b5","article-title":"Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen","volume":"22","author":"Harris","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328160915_DKR269C8","first-page":"367","article-title":"Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-weeks results of the CHEER study","volume":"51","author":"Towner","year":"2009","journal-title":"J AIDS"},{"key":"key\n\t\t\t\t20180328160915_DKR269C9","first-page":"362","article-title":"Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort","volume":"51","author":"Talbot","year":"2009","journal-title":"J AIDS"},{"key":"key\n\t\t\t\t20180328160915_DKR269C10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcv.2009.09.025","article-title":"Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life","volume":"46","author":"Grant","year":"2009","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180328160915_DKR269C11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1545109709331473","article-title":"Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks","volume":"8","author":"Sayana","year":"2009","journal-title":"J Int Assoc Physicians AIDS Care (Chic Ill)"},{"key":"key\n\t\t\t\t20180328160915_DKR269C12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir\u2013ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328160915_DKR269C13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir\u2013ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328160915_DKR269C14","first-page":"1","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2011"},{"key":"key\n\t\t\t\t20180328160915_DKR269C15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAD.0b013e328334cc4a","article-title":"A case of rhabdomiolysis associated with raltegravir use","volume":"24","author":"Dori","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328160915_DKR269C16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dkn429","article-title":"Hepatic safety of tipranavir plus ritonavir (TPV\/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis","volume":"63","author":"Mac\u00edas","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328160915_DKR269C17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2334-9-203","article-title":"Hepatic profile analyses of tipranavir in Phase II and III clinical trials","volume":"9","author":"Mikl","year":"2009","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180328160915_DKR269C18","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/AAC.01486-08","article-title":"Effect of tipranavir\u2013ritonavir on pharmacokinetics of raltegravir","volume":"53","author":"Hanley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328160915_DKR269C19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01827-10","article-title":"Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic sub-study of the EASIER-ANRS 138 trial","author":"Goldwirt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328160915_DKR269C20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/66\/9\/2099\/16862630\/dkr269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:05:33Z","timestamp":1522281933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/66\/9\/2099\/770887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,6,28]]},"published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkr269","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,9]]},"published":{"date-parts":[[2011,6,28]]}}}